Un estudio demuestra que DIFICLIR[TM] ofrece beneficios potenciales (y 2)

        
        1) Cornely A, et al. Fidaxomicin versus vancomycin for infection with
          Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority,
          randomised controlled trial. Lancet Infect Diseases. doi: 10.1016/S1473-3099(11
          )70374-7.
        2) European Centre for Disease Prevention and Control.
          http://ecdc.europa.eu/en/healthtopics/healthcare-associated_...
          . Último acceso enero de 2011.
        3) Simor AE, et al. Clostridium difficile in long-term-care facilities for the
          elderly. Infect Control Hosp Epidemiol. 2002; 23:696-703.
        4) Ananthakrishnan AN. Clostridium difficile infection: epidemiology, risk
          factors and management. Nat Rev Gastroenterol Hepatol. 2011; 8:17-26.
        5) Bouza E, et al. Results of a phase III trial comparing tolevamer, vancomycin
          and metronidazole in patients with Clostridium difficile-associated diarrhoea. Clin
          Micro Infect. 2008; 14(Suppl 7):S103-4.
        6) Lowy I, et al. Treatment with Monoclonal Antibodies against Clostridium
          difficile Toxins. N Engl J Med. 2010; 362; 3:197-205.
        7) Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile
          infection. N Engl J Med. 2011; 364:422-31.
        8) Bauer MP, et al. European Society of Clinical Microbiology and Infectious
          Disease (ESCMID): treatment guidance document for Clostridium difficile-infection
          (CDI). Clin Microbiol Infect. 2009; 15:1067-79.
        9) Food and Drug Administration. FDA approves treatment for Clostridium
          difficile infection [Internet]. [actualizado 27 de mayo de 2011; citado el 16 de
          septiembre de 2011]. Disponible desde
          http://www.fda.gov/NewsEvents/Newsroom/P....
          10) European Commission. Community register of medicinal products for human use.
          http://ec.europa.eu/health/documents/community-register/html.... Último
          acceso marzo de 2012.
          11) McMaster-Baxter NL, Musher DM. Clostridium difficile: recent epidemiologic
          findings and advances in therapy. Pharmacotherapy. 2007; 27:1029-39.
          12) Pepin J, et al. Increasing risk of relapse after treatment of Clostridium
          difficile colitis in Quebec, Canada. Clin Infect Dis. 2005; 40:1591-7.
          13) Ghantoji SS, et al. Economic healthcare costs of Clostridium difficile
          infection: a systematic review. J Hosp Infect. 2010; 74:309-18.
          14) Kyne L, et al. Health care costs and mortality associated with nosocomial
          diarrhea due to Clostridium difficile. Clin Infect Dis. 2002; 1; 34(3):346-53.

CONTACTO: Si desea más información contacte con: Katy Compton-Bishop,Ruder Finn, kcompton-bishop@ruderfinn.co.uk, Tel: +44(0)207-438-3069; MindyDooa, Astellas Pharma Europe Ltd, mindy.dooa@eu.astellas.com, Tel:+44(0)1784-419-444